Novartis will sell Bausch + Lomb its "front of eye" ophthalmology assets for up to $20.5 billion.

Published Date: 07 Jul 2023

For a brief time after the close, Novartis will continue to provide Xiidra to patients on behalf of Bausch + Lomb through transitional agreements.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot